atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
pharma · Recipients of allogeneic stem cell transplantation
AstraZeneca
Astra Zeneca AB
AstraZeneca drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
cambridge, GB HQ
79,242 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- cambridge, GB
- Employees
- 79,242
- Programs
- 1
- Drugs
- 8
- Patents
- 25
AstraZeneca pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AstraZeneca drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
human papillomavirus 9-valent vaccine (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in AstraZeneca's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in AstraZeneca's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.